Robust CD4+ and CD8+ T‐cell depletion in peripheral blood samples of indicated groups was confirmed via flow cytometry staining seven days after initiating tumor vaccine treatment (Figure 1C,D). This evidence concerns the gene CD8A and neoplasm.